- Journal List
- Nutrients
- PMC9824658
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Nutrients. 2023 Jan; 15(1): 160.
Published online 2022 Dec 29. doi:10.3390/nu15010160
PMCID: PMC9824658
PMID: 36615817
Yuanyuan Li, Academic Editor
Author information Article notes Copyright and License information PMC Disclaimer
Associated Data
- Supplementary Materials
- Data Availability Statement
Abstract
Menopause is a physiological change in any woman. Nevertheless, its symptoms could be difficult to accept, and hormone therapy can be sometimes unattractive or contraindicated. Vitamin E components are phytoestrogens, so they are believed to be useful in some indications including menopause. This review aimed to assess the available evidence on the effectiveness of vitamin E in alleviating menopausal symptoms. The Pubmed/MEDLINE, Cochrane Library and Scopus databases were screened. All types of studies that assessed the effectiveness of vitamin E in alleviating menopausal symptoms were included. The PICO question was: “How does vitamin E supplementation affect menopausal symptom occurrence?” The PROSPERO ID number of this review is CRD42022328830. After quality assessment, 16 studies were included in the analysis. The studies were divided into three groups in which the influence of vitamin E on the genital syndrome of menopause, vasomotor symptoms and vascular and metabolic changes were assessed. Vitamin E influences postmenopausal hot flashes, vascular modulation, plasma lipid profile level and vagin*l changes. Compared to vitamin E, estrogen administration leads to better clinical effects. Nevertheless, vitamin E might serve as additive to hormone therapy and its alternative in women with contraindications to estrogens. More quality data are necessary to draw final conclusions.
Keywords: menopause, climacteric, vitamin E, tocopherol, hot flashes
1. Introduction
Menopause is a condition diagnosed retrospectively, by determining the time of the last menstrual period after which the bleeding did not appear for the following 12 months [1]. The average age of menopause worldwide is about 51 years. However, menopause should not be considered as an exact time point. It should rather be perceived as the entire period of changes in the woman’s body functioning, resulting from the cessation of the ovarian hormones release. According to some experts, terms such as the menopausal transition or postmenopause reflect the meaning more precisely [2]. It is estimated that the number of postmenopausal women worldwide will be around 1.1 billion in 2025 [3]. Moreover, the increase in female life expectancy makes menopause an increasing part of a woman’s life. As menopausal symptoms may significantly reduce the quality of life (QoL), providing adequate care and treatment becomes a great clinical challenge worldwide [4].
Menopausal symptoms are related to hormonal changes in the woman’s body. The postmenopausal period is characterized by increased levels of follicle-stimulating hormone (FSH) and decreased levels of estrogen. The clinical picture is complex and affects the patients’ QoL at various levels. The symptoms may be divided into two main groups—vasomotor symptoms and genitourinary syndrome of menopause (GSM). Other symptoms include mood disorders, insomnia, memory or cognitive impairment and others [5,6].
The most common vasomotor symptoms include hot flashes and night sweats, often associated with sleep disorders. According to available data, hormone therapy is the most effective treatment in this indication [7,8]. Treatment should be tailored to the needs and expectations of each patient, considering the individual benefit-risk balance. Nonetheless, numerous patients refuse hormonal therapy due to the fear of its complications or other reasons [9,10,11]. Furthermore, non-pharmacological interventions, such as lifestyle modifications, showed some effectiveness and a significant placebo effect [12].
GSM is defined as a complex of symptoms associated with estrogen deficiency occurring during the menopausal transition. The clinical picture most commonly includes vagin*l dryness, irritation, itching, urinary tract dysfunctions, and dyspaurenia. Despite its frequent occurrence, the syndrome is still underdiagnosed and often untreated. A significant problem is also attributed to either the women’s reluctance to seek consultancy or the unawareness of the disease where women are not perceiving the symptoms as a pathology and accepting them as an inexorable consequence of aging. This makes the diagnosis and the implementation of adequate treatment a great clinical challenge [13,14,15].
For many years the treatment of menopausal symptoms has remained the subject of interest. Menopause hormone therapy is contradicted in numerous cases, e.g., in patients with a history of hormone-dependent tumors, thromboembolism or selected heart diseases. The need for alternative therapeutic options is then substantial [16]. The personalization of therapy is another research direction which is extensively studied nowadays. Alternative drugs may also act as complementary to menopause hormone therapy [17]. Vitamin E is worth mentioning as an alternative/complimentary treatment. Some aut hors proposed the use of vitamin E, due to its antioxidant potential, as a treatment method in a group of patients who do not want or cannot have hormone therapy [18]. Vitamin E is a substance with a strong antioxidant effect. The group of vitamins E includes tocotrienols and tocopherols. Alpha-tocopherol is the most important in the human body, as it shows the greatest biological activity [19]. Vitamin E is fat soluble therefore is found in the human body in plasma lipoproteins. It is also a component of cell membranes. Vitamin E is an exogenous substance, with its dietary source being mainly vegetable oils, grains, meat, and eggs [20]. Due to the ubiquitous presence of vitamin E in food, its deficiency in the body is rare; it may be associated with the malabsorption of lipophilic vitamins. Vitamin E deficiency may be manifested as a tendency to hemolysis and, consequently, hemolytic anemia. Decreased immunity may also be a consequence of its deficiency. The immunosuppressive effect is explained by the improper functioning of immune cells, balance disturbance of the antioxidant system and so the unfavorable effect of free radicals. The anti-allergic, cardio- and neuroprotective or anti-cancer effects of vitamin E remain major subject of research [21,22]. Additionally, the biological effect of vitamin E is explained by the finding that tocopherols and tocotrienols, as phytoestrogens, are the modulators of estrogen receptors. Therefore, proposing the rationale of vitamin E potential utility in the treatment of menopausal symptoms [23].
There are also data concerning the possible effects of vagin*l vitamin E local therapy in the alleviation of GSM symptoms and its potential as an alternative therapy to estrogen therapy. The results of several recent studies are promising as the benefits of short-term treatment and the effectiveness seem comparable to estrogen therapy. However, there is a need for further research to assess the long-term efficacy and safety [24]. There are also studies reporting the effectiveness of vitamin E in relieving vasomotor symptoms such as hot flashes [25,26]. However, data on the use of vitamin E in menopausal symptom treatment are largely incomplete and inconclusive. There are no clear guidelines regarding the treatment, its benefits, safety, or potential complications. Interestingly, according to the British National Institute for Health and Care Excellence (NICE) guidelines for the treatment of breast cancer published in 2022, the use of vitamin E is not recommended in the treatment of menopausal symptoms in patients with breast cancer [27].
Vitamin E is widely recommended by producers of supplements and ‘healthy food’ as a cure for everything. However, the results of studies on the benefits of its supplementation in disease prevention and safety assessment are inconclusive [28]. There are even reports of a possible harmful effect and an increase in the overall mortality in case of unjustified vitamin E supplementation [29]. The relationship between vitamin E and the carcinogenesis process was also a subject of research. Some of available studies found relationship between vitamin E supplementation and an increased risk of developing prostate cancer [30]. Still there is a concern that phytoestrogens, by acting on steroid receptors, may have an adverse effect on the risk of hormone-dependent cancers—especially breast cancer and endometrial cancer [31]. It is possible that the effect depends on the dose and duration of supplementation. However, several studies showed a protective effect on the development of breast cancer [32]. A relationship is also suspected between increased alpha-tocopherol levels and the occurrence of uterine fibroids [33].
The evidence for the efficacy and safety profile of phytoestrogens is limited, and the impact of its supplementation on health remains unclear. Therefore, the question concerning the effectiveness and use of vitamin E in the treatment of menopausal symptoms remains unanswered. The aim of this publication is to systematically review available literature on the effectiveness of vitamin E in the alleviation of menopausal symptoms.
2. Materials and Methods
2.1. Study Design
The current systematic review was performed according to the systematic reviews and meta-analyses (PRISMA) guidelines [34]. The systematic review protocol was registered in PROSPERO database with ID-number: CRD42022328830.
2.2. Search Strategy
The authors screened the following databases: Pubmed/MEDLINE, Cochrane Library and Scopus using the search strategy presented in Table 1.
Table 1
Search strategy.
| Databse | Search Strategy |
|---|---|
| PubMed/MEDLINE | (“Vitamin E”[Mesh] OR (vitamin* AND e) OR tocopherol* OR tocotrienol*) AND (“Menopause”[Mesh] OR menopaus* OR postmenopaus* OR perimenopaus* OR premenopaus* OR climacter*) |
| Scopus | TITLE-ABS-KEY ((vitamin* AND e) OR tocopherol* OR tocotrienol*) AND TITLE-ABS-KEY (menopaus* OR postmenopaus* OR perimenopaus* OR premenopaus* OR climacter*) |
| Cochrane Library | #1”Vitamin E”[Mesh] #2 (vitamin* AND e) OR tocopherol* OR tocotrienol* #3 “Menopause”[Mesh] #4 menopaus* OR postmenopaus* OR perimenopaus* OR premenopaus* OR climacter* AND (#1 OR #2) AND (#3 OR #4) + Trials |
All searches were conducted on 1 August 2022 with languages restricted to English, German or Polish and no publication time limits were imposed.
2.3. Inclusion Criteria
All types of evaluative study designs were included and assessed. Two reviewers (SF and LK) independently screened the studies by the title, abstract and full text. Studies that met the selection criteria were included. Every included study was assessed to the group (0 = not relevant, 1 = possibly relevant, and 2 = very relevant). Only publications that scored at least 1 point were included in the study. Any disagreement was discussed and resolved by the third researcher (MC).
Types of studies: Only original papers according to study designs were eligible for inclusion.
Types of participants: Perimenopausal women.
Types of exposure: Vitamin E intake or its level in the human blood serum.
Types of outcome measures: Perimenopausal or postmenopausal symptoms would be assessed.
Editorials, newspaper articles, and other forms of popular media were excluded. Failure to meet any of the above eligibility criteria resulted in the exclusion from the review, and a third independent reviewer resolved any apparent discrepancies resulting from the selection process. Not appropriate study and control group assessment were exclusion criteria.
2.4. Data Extraction
The PICO question was, “How does vitamin E supplementation affect menopausal symptom occurrence?” Population (P) Perimenopausal women with additional supplementation of vitamin E. Intervention (I) Additional Vitamin E supplementation. Comparison (C) Perimenopausal women without additional supplementation of vitamin E. The outcome (O) Perimenopausal symptoms. Studies (S) included in the analyses were retrospective or prospective. The PRISMA diagram was made according to Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement and was shown in Figure 1 [35].
2.5. Quality Assessment and Risk of Bias
The risk of bias was assessed independently by two authors (SF and LK) using the Newcastle-Ottawa scale [36]. The third reviewer (MC) resolved apparent discrepancies in the selection process. In general, the studies included were of low to moderate quality. It was presented in Supplementary Materials Table S1.
2.6. Synthesis of Results
Due to the heterogeneity of the included studies, it was impossible to perform quantitative synthesis. Nevertheless, all prediction values of the AI methods of the included studies were compared in the groups and presented in Table 2, Table 3 and Table 4.
Table 2
Characteristics of included studies concerning atrophic vaginitis.
| Study | Character of the Study | Number of Participants | Outcomes | |
|---|---|---|---|---|
| Study Group | Control Group | |||
| Ziagham et al. (2012) [37] | The double-blinded randomized controlled trial | 20 postmenopausal women received vagin*l tablets containing 1 mg vitamin E for 8 weeks—daily for 2 weeks, and subsequently, one suppository three days a week | 20 postmenopausal women received vagin*l tablets containing 5 mg of hyaluronic acid sodium salt for 8 weeks—daily for 2 weeks, and subsequently, one suppository three days a week | Both interventions provided relief of vagin*l symptoms, however vagin*l hyaluronic acid group was more effective in reducing the genitourinary symptoms of menopause than vitamin E. |
| Ziagham et al. (2013) [38] | The double-blinded randomized controlled trial | 20 postmenopausal women received vagin*l suppositories containing 1 mg of vitamin E for 8 weeks—daily for 2 weeks, and subsequently, one every other day | 22 postmenopausal women received placebo suppositories with semisynthetic fatty acid triglyceride (placebo) for 8 weeks—daily for 2 weeks, and subsequently, one every other day | vagin*l vitamin E is more effective in reducing the genitourinary symptoms of menopause than placebo. |
| Parnan Emamverdikhan et al. (2016) [39] | The interventional, clinical trial | 26 postmenopausal women received 100 IU vitamin E vagin*l suppositories for 12 weeks—daily for 2 weeks and subsequently twice a week | 26 postmenopausal women received 0.625 mgconjugated estrogen in vagin*l creamfor 12 weeks daily for 2 weeks and subsequently twice a week | Estrogens are more effective in atrophic vaginitis. Nevertheless, vitamin E improve the laboratory signs of vagin*l atrophy. |
| Golmakani et al. (2018) [40] | The single-blinded randomized controlled trial | 26 postmenopausal women received 100 IU vitamin E vagin*l suppository for 12 weeks—daily for 2 weeks and subsequently twice a week | 26 postmenopausal women received 0.625 mg conjugated estrogen in vagin*l cream for 12 weeks—daily for 2 weeks and subsequently twice a week | Vitamin E and estrogens have similar improving potential of sexual function of postmenopausal women. |
Table 3
Characteristics of included studies concerning vasomotor, neurological and psychiatric symptoms of menopause.
| Study | Menopause Symptoms | Character of the Study | Number of Participants | Outcomes | |
| Study Group | Control Group | ||||
| Cancelo Hidalgo et al. (2006) [41] | Menopausal symptoms (Blatt-Kupperman: menopausal index) | The interventional clinical trial | 478 postmenopausal women received isoflavones 120 mg, primrose oil 880 mg and vitamin E 20 mg/day for 6 months. | 447 postmenopausal women received isoflavones 60 mg, primrose oil 440 mg g and vitamin E 10 mg/day or 6 months. | Both doses of supplementation of isoflavones, primrose oil and vitamin E had positive influence on decreasing the menopausal symptoms like nervousness, hot flushes or insomnia. (The influences on methabolic changes was observed and will be described in Table 4). |
| Ziaei et al. (2007) [25] | Hot flashes | The placebo double blind-controlled trial | 51 postmenopausal women received placebo capsule for 4 weeks followed by vitamin E softgel capsule (400 IU/day) for 4 weeks | The reduction in the intensity and frequency of hot flushes is significant greater after vitamin E supplementation than during placebo intake. | |
| Ataei-Almanghadim et al. (2019) [26] | Menopausal symptoms (hot flashes, anxiety, sexual function) | The triple blind randomised controlled trial | 29 postmenopausal women received capsules with vitamin E (400 IU/day) for 8 weeks. | 30 postmenopausal women received 1 g/day curcumin and 30 women received placebo for 8 weeks. | Vitamin E significantly decreased hot flashes in comparison to placebo. The first significant effect was noticed after 8 weeks therapy. No impact on anxiety, sexual function, or menopausal symptoms was found. |
| Farshbaf-Khalili et al. (2022) [42] | Symptoms of menopause (Greene climacteric scale): anxiety, and sexual dysfunction | The triple blind randomised controlled trial | 27 postmenopausal women received 500 mg capsule of vitamin E twice a day for 8 weeks. | 26 postmenopausal women received 1 g/day curcumin and 28 women received placebo (1 g/day microcrystalline cellulose) for 8 weeks. | Vitamin E reduces general menopause symptoms and anxiety in comparison to placebo and curcumin. |
Table 4
Characteristics of included studies concerning lipid profile and vascular changes.
| Study | Menopause Symptoms | Character of the Study | Number of Participants | Outcomes | ||
|---|---|---|---|---|---|---|
| Study Group | Control Group | |||||
| Guetta et al. (1995) [43] | Plasma lipid profile levels (LDL-C, HDL, TC, and TG) | The randomised, interventional clinical trial | 10 postmenopausal women received vitamin E monotherapy (800 IU/day) for 6 weeks | 9 postmenopausal women received a 17 beta-estradiol (0.1 mg/day) patch monotherapy (changed every 3 days) for 3 weeks | During combined phase all included subjects (n = 19) took vitamin E 800 IU/day for 6 weeks, and used the 17B-estradiol patch (changed every 3 days) for the last 3 weeks of this period | Combined administration of estradiol and vitamin E decreases LDL oxidation with no synergism. |
| Wander et al. (1996) [44] | Copper-catalysed oxidation of LDL | The double-blind crossover trial | 48 postmenopausal women received vitamin E (0, 100, 200, and 400 mg/day of a-tocopherol acetate) in different time for 4 weeks, as by the end of the study each subject had received all four doses of vitamin E. 24 women received no estrogens. | 48 postmenopausal women received placebo for 4 weeks. 22 women used oral therapy (0.625 mg estrogens and 10 mg medroxyprogesterone), one used a transdermal patch, and one received estrogen injections. | Vitamin E provides protection LDL from copper-catalysed oxidation. The usage of estrogens and fish oil independently decreases LDL modification. This process is dependent on the vitamin E doses. | |
| Inal et al. (1997) [45] | TC, HDL, VLDL, LDL, MDA, SOD and GSH-Px levels. | The randomised, interventional clinical trial | 22 postmenopausal women received received transdermal estradiol (3 weeks a month) and medroxyprogesterone acetate (10 mg/day) (during the last 10 days of treatment) and vitamin E (600 mg/day) for 6 months. Levels of blood lipids was compared to premenopausal women. | 22 postmenopausal women received transdermal estradiol (0.05 g/day) for 6 months (3 weeks a month). 22 postmenopausal women received transdermal estradiol (3 weeks a month) and medroxyprogesterone acetate (10 mg/day) (during the last 10 days of treatment). The duration of the study was 6 months. Levels of blood lipids was compared to premenopausal women. | Combined therapy with estradiol, medroxyprogesterone acetateand vitamin E leads to improvement in lipid profile. | |
| Koh et al. (1999) [46] | Plasma lipid profile levels (LDL-C, HDL, TC, and TG) | The double-blind, 3-period crossover study | 28 postmenopausal women received vitamin E (800 IU/day) or a combination of the both therapies per day for each of three 6-week treatment periods, with 6 weeks off all therapies between treatment periods. | 28 postmenopausal women received conjugated equine estrogens 0.625 mg/d and placebo or a combination of the both therapies per day for each of three 6-week treatment periods, with 6 weeks off all therapies between treatment periods. | Vitamin E as a supplement to estrogen therapy improves arterial endothelium-dependent vasodilator responsiveness consistent with increased nitric oxide. | |
| Rasool et al. (2003) [47] | arterial stiffness, blood pressure | The randomized, crossover, double-blind, placebo-controlled clinical trial | 10 postmenopausal women received vitamin E (400 IU/day) for 10 weeks. | 10 postmenopausal women received a placebo for 10 weeks. | Vitamin E does not affect arterial stiffness and blood pressure in postmenopausal women. | |
| Ushiroyama et al. (2006) [48] | Chilly sensation. Blood flow measured by laser Doppler under the jaw, in the middle finger, and in the third toe. | The randomised, interventional clinical trial | 60 postmenopausal women received vitamin E (600 mg tocopherol nictinate/day) for 8 weeks. | 60 postmenopausal women received a Wen-jing-tang (7.5 g/day) for 8 weeks. | Wen-jing-tang more effectively improves, in comparison to vitamin E, blood flow in peripheral tissue and is more effective in treatment of chilli sensations. | |
| Cancelo Hidalgo et al. (2006) [41] | Metabolic changes (weight, blood pressure, triglycerides and LDL-level), vasomotor symptoms | The interventional clinical trial | 478 postmenopausal women received isoflavones 120 mg/day, primrose oil 880 mg/day and vitamin E 20 mg/day for 6 months. | 447 postmenopausal women received isoflavones 60 mg/day, primrose oil 440 mg/day g and vitamin E 10 mg/day for 6 months. | Vitamin E, isoflavones and primrose supplementation have no influence on weight or blood pressure. Level of triglycerides and LDL-cholesterol levels tends to decrease, however not significantly | |
| Alves Luzia et al. (2015) [49] | Plasma lipid profile levels (LDL-C, HDL, TC, and TG) | The randomised placebo-controlled trial | 19 postmenopausal women received vitamin E (400 IU/day) and fish oil for 3 months. | 18 postmenopausal women received a placebo for 3 months. 22 postmenopausal women received fish oil for 3 months. | Supplementation of Fish oil plus vitamin E decreases TC and LDL blood level. | |
| Rezasoltani et al. (2021) [50] | Plasma lipid profile levels (LDL-C, HDL, TC, and TG) | The double-blind, placebo-controlled, randomized, cross-over. Phase I/II trial | 41 postmenopausal women received vitamin E (400 IU/day) for 4 weeks and after an 8-day pause period, placebo for next 4 weeks. | 42 postmenopausal women received a placebo for 4 weeks and after an 8-day pause period, vitamin E for next 4 weeks. | Vitamin E showed no significant influence on the lipid profile in menopausal women. | |
TC—Total cholesterol, TG—triglycerides, HDL—high-density lipoprotein cholesterol, VLDL—very low-density lipoprotein cholesterol, LDL—low-density lipoprotein cholesterol, LDL-C—low-density lipoprotein cholesterol, MDA—malondialdehyde, SOD—superoxide dismutase, GSH-Px—glutathione peroxidase, IU—International Units.
3. Results
After quality assessment, applying the inclusion and exclusion criteria, 16 studies were included in the final analysis [25,26,37,38,39,40,41,42,43,44,45,46,47,48,49,50].
To facilitate the analysis, the works were divided into three thematic groups: studies on the influence of vitamin E on vagin*l atrophy, on vasomotor and general symptoms and on vascular changes and metabolic profile. Table 2, Table 3 and Table 4 present the main characteristics of the included studies.
The first group included four studies assessing the influence of vitamin E on the occurrence of atrophic vaginitis (Table 2) [37,38,39,40].
The second group included four studies assessing the influence of vitamin E on vasomotor and other general, especially psychiatric and neurological symptoms in postmenopausal women. Symptoms also included in this group were hot flashes, nervousness, headaches, paraesthesia, insomnia, melancholia, vertigo, fatigue, arthralgia, myalgia, or palpitations (Table 3) [25,26,41,42]. To assess menopausal symptoms and their severety a lot of scales could be used. In included studies, Blatt-Kupperman menopausal index (with symptoms: nervousness, headaches, paraesthesia, insomnia, melancholia, vertigo, fatigue, arthralgia, myalgia, or palpitations) and Greene climacteric scale (assessing vasomotor, somatic, depressive and anxiety symptoms) were used [51,52].
The last group included nine studies assessing the influence of vitamin E on the vascular changes and the lipid profile (Table 4) [41,43,44,45,46,47,48,49,50]. Study of Cancelo Hidalgo et al. already included in the second group was also included in this group since it assessed both aspects.
4. Discussion
Vitamin E influence on menopausal symptoms was first shown in 1995 [43]. Since then only few evidence was shown. The assessed 16 studies vary a lot regarding of symptoms described, the route of vitamin E application, its doses, and the method of evaluation of the results.
4.1. Atrophic Vaginitis
It has been proven that the polyunsaturated cell membrane phospholipids are safeguarded by vitamin E. This effect was shown on the repair function of the human epithelium in the skin and other parts of the body [53]. Both vitamin E and estrogens are important in building of collagen, membrane functioning and metabolism of the cells [54,55]. Accordingly influence of vitamin E on menopausal atrophic changes of vagin*l epithelium is very probable.
Four group of authors analysed the influence of vitamin E on atrophic vaginitis. In all trials the vitamin E was administered vagin*lly.
In both studies, Ziagham et al. from 2012 and from 2013 used the same intervention [37,38]. In the publication from 2013 the superiority of preparations with vitamin E over placebo in terms of both alleviating the symptoms of atrophy and lowering the pH and improving the maturation index has been proven. The publication from 2012 shows the superiority of hyaluronic acid over vitamin E when it comes to alleviating symptoms and the maturation index, with no differences in the effect on vagin*l pH between the preparations.
Research published by Parnan Emamverdikhan et al. and Golmakani et al. were performed on the same group of patients. They proved both objective (vagin*l maturation value) and subjective (Abbreviated Sexual Function Questionnaire) improvement in vagin*l atrophy caused by the use of vagin*l formulation containing vitamin E. Nevertheless, conjugated estrogen cream was found to be superior to vitamin E formula in terms of amelioration of laboratory criteria.
4.2. Vasomotor, Neurologic and Psychiatric Symptoms of Menopause
Hot flashes, also known as vasomotor symptoms, are one of the most common menopausal symptoms which largely impair the QoL. They affect up to 60–80% of women with menopause and persist in about one-third of patients after reaching the age of 60 [56,57]. As the expected length of life in developed countries increases significantly and raising number of women stay active in their professional and personal life, an impairment of the QoL due to hot flashes is a real clinical problem. There are several modalities reducing the intensity and frequency of vasomotor symptoms. The use of hormone therapy is the most effective therapeutic option, but it might be associated with several risks and contraindications [58]. Therefore, this treatment cannot be offered to all menopausal women. The most problematic group of patients includes women after oncological treatment, especially those with a history of breast cancer. Due to chemotherapy or bilateral oophorectomy, they are often abruptly exposed to estrogen deficiency, which may lead to a higher incidence, frequency, and severity of hot flashes. Hormone therapy is contraindicated in patients with a history of estrogen-dependent cancers, e.g., breast cancer. Additionally, they often receive tamoxifen as an adjuvant agent. The reported incidence of hot flashes is especially high and reaches 80% in this particular group. Up to 30% of such patients declared severe symptoms [59]. Non-hormonal therapy, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), might be a good option to consider in such women. Available data confirmed the reduction of the intensity and severity of hot flashes up to 70–80% with the use of these agents [56]. Conversely, the limitation of this type of therapy in tamoxifen-receiving patients is related to the fact that some SSRI/SNRI agents (especially paroxetine and fluoxetine) inhibit CYP2D6 which leads to the reduction of the level of active tamoxifen metabolite (endoxifen) [60,61]. Considering the above, vitamin E offers an opportunity of being an alternative modality. Some research was conducted to assess the efficacy of vitamin E in the reduction of hot flashes. A recent meta-analysis showed that vitamin E combined with omega 3 fatty acids significantly reduced the intensity of hot flashes compared to placebo [62]. According to the authors, the main limitation was a low number of RCTs and small sample size in the analyzed studies. As the data for the general population are encouraging, breast cancer survivors could also benefit from this type of therapy. Vitamin E did not cause side effects compared to gabapentin or clonidine for example, so it is worth investigations as a first-line treatment [63]. Attempts are also made to treat intense symptoms using acupuncture, soy, red clover or black cohosh, but there is currently no evidence to confirm their effectiveness. Good quality data are needed to establish the benefits of vitamin E in the reduction of both the intensity and severity of hot flashes in menopausal woman, especially in the group of patients for whom the type of therapy should be selected very carefully in the context of their medical history.
Four studies investigated the influence of vitamin E on the vasomotor symptoms of menopause, as well as neurological and psychiatric changes during menopause. Cancelo Hidalgo et al. proved a significant effect of an oral supplement containing both 20 and 10 mg/day vitamin E on the improvement of hot flushes and insomnia as well as other parameters measured in the Blatt-Kuperman scale, however given supplement also contained isoflavones and primrose oil [41]. Ziaei et al. and Ataei-Almanghadim et al. supplemented 400 IU/day to included patients. In these studies the beneficial effect on hot flushes was also confirmed [25,26]. On the other hand, Farshbaf-Khalili et al. using the Greene scale, proved the beneficial effect of vitamin E supplementation on anxiety and the overall score on this scale by supplementation of 500 mg of vitamin E twice a day [42]. In all asesed studies a positive effect on discussed menopausal symptoms was shown. Nevertheless, the doses used differed. The release of the symptoms was shown in all studies. As effect of vitamin E might be doses-dependend, the toxical influence on the organism should not be forgotten. Further studies should be performed to estimate the most effective and the less harmful dose of vitamin E in vasomotor, neurologic or psychiatric symptoms release.
4.3. Influence on the Lipid Profile and Vascular Changes
It is well known that the incidence of cardiovascular disease (CVD) increases dramatically after menopause [64]. While it is related to the natural aging of the body, but hormonal changes play an invaluable clear role. Increase in cardiovascular risk was found to be particularly pronounced in women with premature ovarian failure [65]. Lipid metabolism and its disorders are among the most important modifiable risk factors for CVD. Menopause is a period in women’s lives which is associated with a significant deterioration of the lipid profile. A recent meta-analysis conducted by Ambikairajah et al. revealed that postmenopausal women had higher levels of triglycerides (TG) and low-density lipoproteins (LDL) compared to premenopausal women [66]. Total cholesterol, LDL and TG concentrations were lower in premenopausal women than in men, while high density lipoprotein cholesterol (HDL) concentration was higher than in men [67,68]. Thereafter, the LDL fraction in women was increased by about 2 mg/dL per year between the ages 40 and 60, which included both premenopausal age and mainly postmenopausal years [69,70]. Studies on changes in HDL concentration are inconsistent [67,71]. The above-described changes are mainly due to both estrogen deficiency and the increase in levels of free androgens [65]. The effects of menopause on the lipid profile may be partially reduced by hormone replacement therapy, mainly in terms of reducing LDL levels and increasing HDL levels [72,73].
Vitamin E is considered an element in dyslipidaemia treatment regimen. It decreased lipid peroxidation both in vitro and in vivo by breaking chain propagation [72]. Moreover, it was demonstrated that vitamin E suppressed atherogenesis via influencing the endothelial and arterial smooth muscle cells [73,74]. In addition, supplementation with vitamin E ameliorated LDL resistance to oxidation propagation [74]. Although research results are inconsistent, some studies indicated that vitamin E supplementation might improve selected parameters of the lipid profile [46,50,75]. Few large-scale studies of dietary vitamin E intake showed a positive effect in reducing the risk of coronary heart disease in both men and women [76,77]. It was also confirmed in postmenopausal women with only dietary intake [78]. Wang et al. studied a group of Chinese women with metabolic syndrome and demonstrated that four-month of vitamin E supplementation at a dose of 300 IU/day lowered total cholesterol (TC), although it should be mentioned that it also significantly reduced HDL [79]. Vitamin E and omega-3 fatty acids co-supplementation was proved to reduce the levels of VLDL [74]. Moreover, several studies showed a beneficial effect on lowering the risk of cardiovascular disease, especially in population at risk with pre-existing diseases [80,81]. Conversely, it should be mentioned that apart from articles that showed no significant effect of the intake of vitamin E on the lipid profile and cardiovascular risk, there are also studies that indicated a negative effect of vitamin E supplementation in some groups of patients. A study conducted in a male smokers group showed that alpha-tocopherol supplementation was associated with more deaths from hemorrhagic stroke compared to placebo [82]. Furthermore, a meta-analysis of clinical trials showed that the majority of trials testing high-dose supplementation of vitamin E demonstrated an increase in all-cause mortality when compared to the control group [29].
Nine of the included studies investigated the influence of vitamin E on the lipid profile level and other vascular changes. Studies from Rezasoltani et al., Cancelo Hidalgo et al. and Rasool et al. did not show the influence vitamin E supplementation on lipid profile and/or postmenopausal arterial remodulation, respectively [47,50]. On the other hand, Koh et al. also demonstrated no effect of vitamin E on lipid profile and vascular disease markers, however showed improvement in arterial endothelium-dependent vasodilator responsiveness [46]. Ushiroyama et al. proved the superior effect of Wen-jing-tang over 600 mg/day vitamin E intake on the regulation of peripheral blood flow [48]. Alves Luzia et al. and Wander et al. have proven the positive influence of combined treatment with vitamin E with fish oil on lipid profile and oxidation, whereas Cancelo Hidaldo et al. showed improvement in vasomotor symptoms after vitamin E, isoflavones and primrose oil supplementation [41,44,49]. Inal et al. proved that combined administration of estrogens and vitamin E improve lipid profile, whereas Guetta et al. found independent positive effect of these substances on lipid oxidation [43,45].
4.4. Summary of Evidence
Vitamin E was shown by some studies to influence postmenopausal vasomotor symptoms, plasma lipid profile, vascular, psychiatric, neurological as well as and vagin*l changes. In competetive studies the superiority of estrogens vs. vitamin E in menopausal symptom reduction was apparent. Nevertheless, vitamin E seem to be an excellent addition to hormone therapy or effective as monotherapy in women contraindicated to estrogen therapy. Estrogen/vitamin E combination treatment could lead to a better effect of the hormone therapy or to fewer side effects since the used dose of estrogens should be reduced. Very few studies were conducted to evaluate the combined therapy (estrogens with vitamin E) [40,46]. Moreover, no studies compared the combined therapy of hyaluronic acid with vitamin E, which could be a better option than hyaluronic acid alone in patients contraindicated to estrogens. Conversely, vitamin E’s effectiveness is difficult to conclude from this review because of the heterogeneity of the doses. The mean vitamin E dose was difficult to assess as different routesof medicament application, different compounds and different units (IU or mg) were used.. Only one study was identified to compare the effectiveness of different vitamin E doses, so future investigation in this field could offer the medical provider detailed information about vitamin E effectiveness and safety.
Moreover, antidepressant medications, including SSRI and SNRI, are used to decrease psychosomatic and vasomotor symptoms [83]. As was shown in the review, vitamin E alone could influence psychological issues [25,26,41]. The additional influence of the placebo effect improves the women’s well-being. A combination of these three methods could lead to a decrease in the psychological and vasomotor symptoms of menopause.
4.5. Limitations
Our study has several limitations. First of all, there was a problem with the synthesis of the results because of the heterogeneity of the studies. Therefore, several deviations in the groups were made to approximate the similar outcomes of the assessed studies. Unfortunately, this was insufficient because of methodological differences and incomparable doses of vitamin E and heterogeneity of control groups, where sometimes estrogens were used. Moreover, the average quality of included studies was low to moderate, with very small groups, as only five studies have participant rate over 50 persons in each control and study group. To better interpretation of influence of vitamin E on menopause symptoms assessment in three groups was performed.
5. Conclusions
Vitamin E influences postmenopausal symptoms like hot flashes, vascular modulation, plasma lipid profile level and vagin*l changes. In comparison with vitamin E, estrogen administration leads to better clinical effects. Nevertheless, vitamin E might become an option as an addition to standard hormone therapy. It might be used as an alternative compound in symptomatic patients with contraindications to estrogens (e.g., cancer survivors). More good quality data are necessary to draw final conclusions.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15010160/s1. Table S1. The Newcastle-Ottawa scale for quality assessment of included studies.
Click here for additional data file.(113K, zip)
Funding Statement
Financial Support: Centre of Postgraduate Medical Education, Warsaw, Poland; number: 501-1-022-26-22.
Author Contributions
Conceptualization, M.C. and S.F.; methodology, S.F.; formal analysis, M.Z.; investigation, S.F. and L.K.; resources, M.B. (Monika Bączkowska) and M.B. (Maciej Byrczak); data curation, L.K., M.B. (Monika Bączkowska) and M.Z.; writing—original draft preparation, S.F., K.G. and L.K.; writing—review and editing, M.C., M.Z. and M.A.; visualization, K.G. and J.K.; supervision, M.C.; project administration, K.G., M.A. and J.K.; funding acquisition, M.B. (Monika Bączkowska) and M.C. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare that they have no known competing financial interest or personal relationship that could have appeared to influence the work reported in this paper.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
1. Greendale G.A., Lee N.P., Arriola E.R. The menopause. Lancet. 1999;353:571–580. doi:10.1016/S0140-6736(98)05352-5. [PubMed] [CrossRef] [Google Scholar]
2. Takahashi T.A., Johnson K.M. Menopause. Med. Clin. N. Am. 2015;99:521–534. doi:10.1016/j.mcna.2015.01.006. [PubMed] [CrossRef] [Google Scholar]
3. Shifren J.L., Gass M.L.S. NAMS Recommendations for Clinical Care of Midlife Women Working Group The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21:1038–1062. doi:10.1097/GME.0000000000000319. [PubMed] [CrossRef] [Google Scholar]
4. Al-Safi Z.A., Polotsky A.J. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol. 2015;29:548–553. doi:10.1016/j.bpobgyn.2014.12.002. [PubMed] [CrossRef] [Google Scholar]
5. Minkin M.J. Menopause: Hormones, Lifestyle, and Optimizing Aging. Obstet. Gynecol Clin. N. Am. 2019;46:501–514. doi:10.1016/j.ogc.2019.04.008. [PubMed] [CrossRef] [Google Scholar]
6. Santoro N., Epperson C.N., Mathews S.B. Menopausal Symptoms and Their Management. Endocrinol. Metab. Clin. N. Am. 2015;44:497–515. doi:10.1016/j.ecl.2015.05.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Stuenkel C.A., Davis S.R., Gompel A., Lumsden M.A., Murad M.H., Pinkerton J.V., Santen R.J. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2015;100:3975–4011. doi:10.1210/jc.2015-2236. [PubMed] [CrossRef] [Google Scholar]
8. The North American Menopause Society The NAMS 2017 Hormone Therapy Position Statement Advisory Panel The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24:728–753. doi:10.1097/GME.0000000000000921. [PubMed] [CrossRef] [Google Scholar]
9. Lobo R.A. Where are we 10 years after the Women’s Health Initiative? J. Clin. Endocrinol. Metab. 2013;98:1771–1780. doi:10.1210/jc.2012-4070. [PubMed] [CrossRef] [Google Scholar]
10. Cagnacci A., Venier M. The Controversial History of Hormone Replacement Therapy. Medicina. 2019;55:602. doi:10.3390/medicina55090602. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Cagnacci A., Gambacciani M., Gallo M., Lello S. Executive Committee of the Italian Society of Menopause (SIM) and of the Italian Society of Gynecology of the Third Age (SIGiTE) Recommendations on menopausal hormone replacement therapy. Minerva Ginecol. 2019;71:395–403. doi:10.23736/S0026-4784.19.04500-3. [PubMed] [CrossRef] [Google Scholar]
12. Pachman D.R., Jones J.M., Loprinzi C.L. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int. J. Womens Health. 2010;2:123–135. doi:10.2147/ijwh.s7721. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Shifren J.L. Genitourinary Syndrome of Menopause. Clin. Obstet. Gynecol. 2018;61:508–516. doi:10.1097/GRF.0000000000000380. [PubMed] [CrossRef] [Google Scholar]
14. Shim S., Park K.M., Chung Y.J., Kim M.R. Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. J. Menopausal Med. 2021;27:1–7. doi:10.6118/jmm.20034. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Nappi R.E., Martini E., Cucinella L., Martella S., Tiranini L., Inzoli A., Brambilla E., Bosoni D., Cassani C., Gardella B. Addressing Vulvovagin*l Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front. Endocrinol. 2019;10:561. doi:10.3389/fendo.2019.00561. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Al-Safi Z.A., Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil. Steril. 2014;101:905–915. doi:10.1016/j.fertnstert.2014.02.032. [PubMed] [CrossRef] [Google Scholar]
17. Johnson A., Roberts L., Elkins G. Complementary and Alternative Medicine for Menopause. J. Evid.-Based Integr. Med. 2019;24:2515690X19829380. doi:10.1177/2515690X19829380. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Milewicz A., Demissie M., Zatonska K., Jedrzejuk D., Tworowska U., Ilow R., Biernat J. Influence of dietary and genetic factors on metabolic status in obese and lean postmenopausal women. Gynecol. Endocrinol. 2003;17:333–338. doi:10.1080/gye.17.4.333.338. [PubMed] [CrossRef] [Google Scholar]
19. Szewczyk K., Chojnacka A., Górnicka M. Tocopherols and Tocotrienols-Bioactive Dietary Compounds; What Is Certain, What Is Doubt? Int. J. Mol. Sci. 2021;22:6222. doi:10.3390/ijms22126222. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Wang X., Quinn P.J. Vitamin E and its function in membranes. Prog. Lipid Res. 1999;38:309–336. doi:10.1016/S0163-7827(99)00008-9. [PubMed] [CrossRef] [Google Scholar]
21. Mustacich D.J., Vo A.T., Elias V.D., Payne K., Sullivan L., Leonard S.W., Traber M.G. Regulatory Mechanisms to Control Tissue α-Tocopherol. Free Radic. Biol. Med. 2007;43:610–618. doi:10.1016/j.freeradbiomed.2007.05.027. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Miyazawa T., Burdeos G.C., Itaya M., Nakagawa K., Miyazawa T. Vitamin E: Regulatory Redox Interactions. IUBMB Life. 2019;71:430–441. doi:10.1002/iub.2008. [PubMed] [CrossRef] [Google Scholar]
23. Khallouki F., de Medina P., Caze-Subra S., Bystricky K., Balaguer P., Poirot M., Silvente-Poirot S. Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds. Front. Oncol. 2015;5:287. doi:10.3389/fonc.2015.00287. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Porterfield L., Santiago Delgado Z., Song A., Syed F., Wur N. Is vagin*l vitamin E effective in reducing the symptoms of genitourinary syndrome of menopause? Evid.-Based Pract. 2022;25:33–34. doi:10.1097/EBP.0000000000001412. [CrossRef] [Google Scholar]
25. Ziaei S., Kazemnejad A., Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol. Obstet. Investig. 2007;64:204–207. doi:10.1159/000106491. [PubMed] [CrossRef] [Google Scholar]
26. Ataei-Almanghadim K., Farshbaf-Khalili A., Ostadrahimi A., Shaseb E., Mirghafourvand M. The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: A triple blind randomised controlled trial. Complement. Ther. Med. 2019;48:102267. doi:10.1016/j.ctim.2019.102267. [PubMed] [CrossRef] [Google Scholar]
27. Iacobucci G. NICE recommends new targeted treatment for early breast cancer. BMJ. 2022;377:o1491. doi:10.1136/bmj.o1491. [PubMed] [CrossRef] [Google Scholar]
28. Wierzejska R. Evaluation of prenatal vitamin-mineral preparations in the context of recommended dietary supplementation. Are pregnant women supplied with what they should get? Rocz. Państwowego Zakładu Hig. 2021;72:309–320. doi:10.32394/rpzh.2021.0176. [PubMed] [CrossRef] [Google Scholar]
29. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005;142:37–46. doi:10.7326/0003-4819-142-1-200501040-00110. [PubMed] [CrossRef] [Google Scholar]
30. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., Minasian L.M., Ford L.G., Parnes H.L., Gaziano J.M., et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2011;306:1549–1556. doi:10.1001/jama.2011.1437. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Rowe I.J., Baber R.J. The effects of phytoestrogens on postmenopausal health. Climacteric. 2021;24:57–63. doi:10.1080/13697137.2020.1863356. [PubMed] [CrossRef] [Google Scholar]
32. Bilal I., Chowdhury A., Davidson J., Whitehead S. Phytoestrogens and prevention of breast cancer: The contentious debate. World J. Clin. Oncol. 2014;5:705–712. doi:10.5306/wjco.v5.i4.705. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Ciebiera M., Szymańska-Majchrzak J., Sentkowska A., Kilian K., Rogulski Z., Nowicka G., Jakiel G., Tomaszewski P., Włodarczyk M. Alpha-Tocopherol Serum Levels Are Increased in Caucasian Women with Uterine Fibroids: A Pilot Study. Biomed. Res. Int. 2018;2018:6793726. doi:10.1155/2018/6793726. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
34. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi:10.1371/journal.pmed.1000097. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
35. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med. 2009;6:e1000100. doi:10.1371/journal.pmed.1000100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Margulis A.V., Pladevall M., Riera-Guardia N., Varas-Lorenzo C., Hazell L., Berkman N.D., Viswanathan M., Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clin. Epidemiol. 2014;6:359–368. doi:10.2147/CLEP.S66677. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Ziagham S. Effect of hyaluronic acid and vitamin E vagin*l tablets on atrophic vaginitis: A randomized controlled trial. Afr. J. Pharm. Pharmacol. 2012;6:3124–3129. doi:10.5897/AJPP12.433. [CrossRef] [Google Scholar]
38. Ziagham S., Abbaspoor Z., Safyari S., Rad P. Effect of vitamin E vagin*l suppository on atrophic vaginitis among postmenopausal women. Jundishapur J. Chronic Dis. Care. 2013;2:32255. [Google Scholar]
39. Parnan Emamverdikhan A., Golmakani N., Tabassi S., Hassanzadeh M., Sharifi N., Shakeri M. A survey of the therapeutic effects of Vitamin E suppositories on vagin*l atrophy in postmenopausal women. Iran. J. Nurs. Midwifery Res. 2016;21:475–481. doi:10.4103/1735-9066.193393. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
40. Golmakani N., Parnan Emamverdikhan A., Zarifian A., Sajadi Tabassi S., Hassanzadeh M. Vitamin E as alternative local treatment in genitourinary syndrome of menopause: A randomized controlled trial. Int. Urogynecology J. 2018;30:831–837. doi:10.1007/s00192-018-3698-z. [PubMed] [CrossRef] [Google Scholar]
41. Cancelo Hidalgo M., Castelo-Branco C., Blumel J., Lanchares Pérez J., Alvarez De Los Heros J. Effect of a compound containing isoflavones, primrose oil and vitamin E in two different doses on climacteric symptoms. J. Obstet. Gynaecol. 2006;26:344–347. doi:10.1080/01443610600613417. [PubMed] [CrossRef] [Google Scholar]
42. Farshbaf-Khalili A., Ostadrahimi A., Mirghafourvand M., Ataei-Almanghadim K., Dousti S., Iranshahi A.M. Clinical Efficacy of Curcumin and Vitamin E on Inflammatory-Oxidative Stress Biomarkers and Primary Symptoms of Menopause in Healthy Postmenopausal Women: A Triple-Blind Randomized Controlled Trial. J Nutr. Metab. 2022;2022:6339715. doi:10.1155/2022/6339715. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Guetta V., Panza J., Waclawiw M., Cannon R. Effect of combined 17 beta-estradiol and vitamin E on low-density lipoprotein oxidation in postmenopausal women. Am. J. Cardiol. 1995;75:1274–1276. doi:10.1016/S0002-9149(99)80780-2. [PubMed] [CrossRef] [Google Scholar]
44. Wander R., Du S., Ketchum S., Rowe K. Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy. Am. J. Clin. Nutr. 1996;63:184–193. doi:10.1093/ajcn/63.2.184. [PubMed] [CrossRef] [Google Scholar]
45. Inal M., Sunal E., Kanbak G., Zeytinoglu S. Effects of postmenopausal hormone replacement and alpha-tocopherol on the lipid profiles and antioxidant status. Clin. Chim. Acta Int. J. Clin. Chem. 1997;268:21–29. doi:10.1016/S0009-8981(97)00153-8. [PubMed] [CrossRef] [Google Scholar]
46. Koh K., Blum A., Hathaway L., Mincemoyer R., Csako G., Waclawiw M., Panza J., Cannon R. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation. 1999;100:1851–1857. doi:10.1161/01.CIR.100.18.1851. [PubMed] [CrossRef] [Google Scholar]
47. Rasool A., Rehman A., Wan Yusuf W., Rahman A. Vitamin E and its effect on arterial stiffness in postmenopausal women—A randomized controlled trial. Int. J. Clin. Pharmacol. Ther. 2003;41:587–592. doi:10.5414/CPP41587. [PubMed] [CrossRef] [Google Scholar]
48. Ushiroyama T., Sakuma K., Nosaka S. Comparison of effects of vitamin E and wen-jing-tang (unkei-to), an herbal medicine, on peripheral blood flow in post-menopausal women with chilly sensation in the lower extremities: A randomized prospective study. Am. J. Chin. Med. 2006;34:969–979. doi:10.1142/S0192415X06004442. [PubMed] [CrossRef] [Google Scholar]
49. Alves Luzia L., Mendes Aldrighi J., Teixeira Damasceno N., Rodrigues Sampaio G., Aparecida Manólio Soares R., Tande Silva I., De Queiroz Mello A., Ferreira Carioca A., Ferraz da Silva Torres E. Fish oil and vitamin e change lipid profiles and anti-ldl-antibodies in two different ethnic groups of women transitioning through menopause. Nutr. Hosp. 2015;32:165–174. doi:10.3305/nh.2015.32.1.9079. [PubMed] [CrossRef] [Google Scholar]
50. Rezasoltani P., Elliyoun N., Ziaie T., Sobhani A., Leyli E., Aski S. Double-blind controlled trial of vitamin e effects on serum lipid profile in menopausal women. Diabetes Metab. Syndr. Obes. Targets Ther. 2021;14:1053–1060. doi:10.2147/DMSO.S233138. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
51. Cruz E.F., Nina V.J.d.S., Figuerêdo E.D. Climacteric Symptoms and Sexual Dysfunction: Association between the Blatt-Kupperman Index and the Female Sexual Function Index. Rev. Bras Ginecol. Obs. 2017;39:66–71. doi:10.1055/s-0037-1598603. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Greene J.G. Constructing a standard climacteric scale. Maturitas. 1998;29:25–31. doi:10.1016/S0378-5122(98)00025-5. [PubMed] [CrossRef] [Google Scholar]
53. Thompson M.A., Zuniga K., Sousse L., Christy R., Gurney C.J. The Role of Vitamin E in Thermal Burn Injuries, Infection, and Sepsis: A Review. J. Burn. Care Res. 2022;43:1260–1270. doi:10.1093/jbcr/irac100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Kendall A.C., Pilkington S.M., Wray J.R., Newton V.L., Griffiths C.E.M., Bell M., Watson R.E.B., Nicolaou A. Menopause induces changes to the stratum corneum ceramide profile, which are prevented by hormone replacement therapy. Sci. Rep. 2022;12:21715. doi:10.1038/s41598-022-26095-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Calabrese V., Scapagnini G., Catalano C., Bates T.E., Geraci D., Pennisi G., Giuffrida Stella A.M. Regulation of heat shock protein synthesis in human skin fibroblasts in response to oxidative stress: Role of vitamin E. Int. J. Tissue React. 2001;23:127–135. [PubMed] [Google Scholar]
56. Nelson H.D. Menopause. Lancet. 2008;371:760–770. doi:10.1016/S0140-6736(08)60346-3. [PubMed] [CrossRef] [Google Scholar]
57. Santoro N., Roeca C., Peters B.A., Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J. Clin. Endocrinol. Metab. 2021;106:1–15. doi:10.1210/clinem/dgaa764. [PubMed] [CrossRef] [Google Scholar]
58. Freedman R.R. Menopausal hot flashes: Mechanisms, endocrinology, treatment. J. Steroid Biochem. Mol. Biol. 2014;142:115–120. doi:10.1016/j.jsbmb.2013.08.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Jin Y., Hayes D.F., Li L., Robarge J.D., Skaar T.C., Philips S., Nguyen A., Schott A., Hayden J., Lemler S., et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J. Clin. Oncol. 2008;26:5849–5854. doi:10.1200/JCO.2008.16.8377. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
60. Santen R.J., Song Y., Wang J.-P., Yue W. Preclinical breast effects of a tissue selective estrogen complex (TSEC) including conjugated estrogen with bazedoxifene. J. Steroid Biochem. Mol. Biol. 2017;170:61–64. doi:10.1016/j.jsbmb.2016.05.008. [PubMed] [CrossRef] [Google Scholar]
61. Bardia A., Novotny P., Sloan J., Barton D., Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: A pooled analysis. Menopause. 2009;16:477–483. doi:10.1097/gme.0b013e31818c91ca. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
62. Maghalian M., Hasanzadeh R., Mirghafourvand M. The effect of oral vitamin E and omega-3 alone and in combination on menopausal hot flushes: A systematic review and meta-analysis. Post Reprod. Health. 2022;28:93–106. doi:10.1177/20533691221083196. [PubMed] [CrossRef] [Google Scholar]
63. Drewe J., Bucher K.A., Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015;4:65. doi:10.1186/s40064-015-0808-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
64. Schnatz P.F. Hormonal therapy: Does it increase or decrease cardiovascular risk? Obstet. Gynecol. Surv. 2006;61:673–681. doi:10.1097/01.ogx.0000238674.98471.bb. [PubMed] [CrossRef] [Google Scholar]
65. Anagnostis P., Theocharis P., Lallas K., Konstantis G., Mastrogiannis K., Bosdou J.K., Lambrinoudaki I., Stevenson J.C., Goulis D.G. Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. Maturitas. 2020;135:74–79. doi:10.1016/j.maturitas.2020.03.006. [PubMed] [CrossRef] [Google Scholar]
66. Ambikairajah A., Walsh E., Cherbuin N. Lipid profile differences during menopause: A review with meta-analysis. Menopause. 2019;26:1327–1333. doi:10.1097/GME.0000000000001403. [PubMed] [CrossRef] [Google Scholar]
67. Gardner C.D., Tribble D.L., Young D.R., Ahn D., Fortmann S.P. Population frequency distributions of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use: The Stanford Five City Project. Prev. Med. 2000;31:335–345. doi:10.1006/pmed.2000.0715. [PubMed] [CrossRef] [Google Scholar]
68. Williams J.K., Suparto I. Hormone replacement therapy and cardiovascular disease: Lessons from a monkey model of postmenopausal women. ILAR J. 2004;45:139–146. doi:10.1093/ilar.45.2.139. [PubMed] [CrossRef] [Google Scholar]
69. van Beresteijn E.C., Korevaar J.C., Huijbregts P.C., Schouten E.G., Burema J., Kok F.J. Perimenopausal increase in serum cholesterol: A 10-year longitudinal study. Am. J. Epidemiol. 1993;137:383–392. doi:10.1093/oxfordjournals.aje.a116686. [PubMed] [CrossRef] [Google Scholar]
70. Jensen J., Nilas L., Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 1990;12:321–331. doi:10.1016/0378-5122(90)90012-U. [PubMed] [CrossRef] [Google Scholar]
71. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N. Engl. J. Med. 1989;321:641–646. doi:10.1056/NEJM198909073211004. [PubMed] [CrossRef] [Google Scholar]
72. O’Brien S.N., Anandjiwala J., Price T.M. Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use. Obstet. Gynecol. 1997;90:244–248. doi:10.1016/S0029-7844(97)00212-3. [PubMed] [CrossRef] [Google Scholar]
73. LaRosa J.C. Outcomes of lipid-lowering treatment in postmenopausal women. Drugs Aging. 2002;19:595–604. doi:10.2165/00002512-200219080-00005. [PubMed] [CrossRef] [Google Scholar]
74. Sepidarkish M., Morvaridzadeh M., Akbari-Fakhrabadi M., Almasi-Hashiani A., Rezaeinejad M., Heshmati J. Effect of omega-3 fatty acid plus vitamin E Co-Supplementation on lipid profile: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13:1649–1656. doi:10.1016/j.dsx.2019.03.018. [PubMed] [CrossRef] [Google Scholar]
75. Tefa*gh G., Payab M., Qorbani M., Sharifi F., Sharifi Y., Ebrahimnegad Shirvani M.S., Pourghazi F., Atlasi R., Shadman Z., Rezaei N., et al. Effect of vitamin E supplementation on cardiometabolic risk factors, inflammatory and oxidative markers and hormonal functions in PCOS (polycystic ovary syndrome): A systematic review and meta-analysis. Sci. Rep. 2022;12:5770. doi:10.1038/s41598-022-09082-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
76. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 1993;328:1444–1449. doi:10.1056/NEJM199305203282003. [PubMed] [CrossRef] [Google Scholar]
77. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993;328:1450–1456. doi:10.1056/NEJM199305203282004. [PubMed] [CrossRef] [Google Scholar]
78. Kushi L.H., Folsom A.R., Prineas R.J., Mink P.J., Wu Y., Bostick R.M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N. Engl. J. Med. 1996;334:1156–1162. doi:10.1056/NEJM199605023341803. [PubMed] [CrossRef] [Google Scholar]
79. Wang Q., Sun Y., Ma A., Li Y., Han X., Liang H. Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome. Int. J. Vitam. Nutr. Res. 2010;80:178–187. doi:10.1024/0300-9831/a000015. [PubMed] [CrossRef] [Google Scholar]
80. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet. 2000;356:1213–1218. doi:10.1016/S0140-6736(00)02783-5. [PubMed] [CrossRef] [Google Scholar]
81. Stephens N. Anti-oxidant therapy for ischaemic heart disease: Where do we stand? Lancet. 1997;349:1710–1711. doi:10.1016/S0140-6736(97)22024-6. [PubMed] [CrossRef] [Google Scholar]
82. Steiner M., Glantz M., Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am. J. Clin. Nutr. 1995;62:1381S–1384S. doi:10.1093/ajcn/62.6.1381S. [PubMed] [CrossRef] [Google Scholar]
83. Newhouser L.M., Maneval M., Rayalam K., Sabeeh G., Varela L. SSRIs vs. SNRIs for Vasomotor Symptoms of Menopause. Am. Fam. Physician. 2022;105:430–431. [PubMed] [Google Scholar]
Articles from Nutrients are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)
